

Akzo Nobel confident over pensions disagreement

Arnhem, The Netherlands, February 3, 2006 – Akzo Nobel Nederland B.V. and Akzo Nobel's pension fund have received a summons from the Association of Retired Akzo Nobel Employees with regards to the new financing of the company's Dutch pension scheme.

Although the new pension set-up was agreed by the company and the unions at the end of June 2005, the Association has initiated court proceedings requesting a legal ruling that the new arrangements should not be applied to its members.

Under the terms of the agreement with the unions—which was supported by external expert studies—the new financing arrangements replaced the defined benefit scheme with a defined contribution scheme and substantially improved the financial position of the pension fund.

Based on legal advice, Akzo Nobel Nederland and the pension fund have full confidence in a positive outcome of the proceedings.

Furthermore, Akzo Nobel is of the opinion that not only is the new arrangement fair with respect to all participants in the Dutch Pension Fund, but it also serves the continuity of the company in the interests of all employees, both active and retired.

- - -

Note for the editor

Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Listed on both the Euronext and NASDAQ Stock Exchanges, the company is a member of the Dow Jones Sustainability Index. Consolidated revenues for 2004 totaled EUR 12.7 billion. The Company currently employs some 62,000 people in more than 80 countries. The financial results for 2005 will be published on February 7, 2006.

Internet: www.akzonobel.nl

Not for publication – for more information

Akzo Nobel Nederland bv
Contact: Paul van der Boor, tel. 026 - 366 3713 / 026 - 366 43 43

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook", should be carefully considered and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please refer to our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.

Akzo Nobel Nederland bv
Velperweg 76
Postbus 9300
6800 SB Arnhem
Tel. (026) 366 37 13
Fax (026) 366 55 60